Cancer cell permeability-glycoprotein as a target of MDR reverters: possible role of novel dihydropyridine derivatives
- PMID: 16918323
- DOI: 10.2174/138945006778019336
Cancer cell permeability-glycoprotein as a target of MDR reverters: possible role of novel dihydropyridine derivatives
Erratum in
- Curr Drug Targets. 2006 Dec;7(12):1729. Kawase, M [added]; Shah, A [added]; Motohashi, N [added]
Abstract
The overexpression of permeability-glycoprotein (P-gp) and other drug transporters (ATP-binding cassette) confers a multidrug resistance (MDR) phenotype on cells in various diseases, including many forms of cancer. Development of MDR is one of the main reasons of failure in malignant tumour chemotherapy, as tumour cells, by increasing drug efflux, acquire cross-resistance to many structurally and functionally unrelated anticancer agents, which therefore never achieve effective intracellular concentrations. Endeavouring to find MDR-reverters is a crucial task for exploring new anti-cancer therapeutic intervention. Although many P-gp inhibitors have so far been identified, it is widely recognised that their interaction with P-gp is a complex process and, presently, the details of the mechanisms of action are still a matter of debate. These compounds turned out, however, to be of limited clinical usefulness owing to their inherent pharmacological activities (first generation compounds) and their accessory, inhibiting activity on CYP enzyme system (second generation compounds). Moreover, recent advances of the knowledge on P-gp structure and function and on the mechanisms of P-gp inhibition will prove fruitful for the development of novel therapeutically effective P-gp inhibitors. A dibenzoyl-1,4-dihydropyridine compound (DP7) has been shown to be a powerful P-gp inhibitor, almost devoid of cardiovascular effects, but capable of inhibiting liver CYP3A. DP7 is considered a lead compound for the development of novel dihydropyridines which do not affect CYP enzyme system but still retain the activity towards ABC-efflux transporters.
Similar articles
-
Multidrug resistance: retrospect and prospects in anti-cancer drug treatment.Curr Med Chem. 2006;13(16):1859-76. doi: 10.2174/092986706777585077. Curr Med Chem. 2006. PMID: 16842198 Review.
-
5-Oxo-hexahydroquinoline Derivatives and Their Tetrahydroquinoline Counterparts as Multidrug Resistance Reversal Agents.Molecules. 2020 Apr 16;25(8):1839. doi: 10.3390/molecules25081839. Molecules. 2020. PMID: 32316291 Free PMC article.
-
Understanding of human ATP binding cassette superfamily and novel multidrug resistance modulators to overcome MDR.Biomed Pharmacother. 2018 Apr;100:335-348. doi: 10.1016/j.biopha.2018.02.038. Epub 2018 Feb 16. Biomed Pharmacother. 2018. PMID: 29453043 Review.
-
β-carotene reverses multidrug resistant cancer cells by selectively modulating human P-glycoprotein function.Phytomedicine. 2016 Mar 15;23(3):316-23. doi: 10.1016/j.phymed.2016.01.008. Epub 2016 Feb 6. Phytomedicine. 2016. PMID: 26969385
-
Reversal of multidrug resistance by Marsdenia tenacissima and its main active ingredients polyoxypregnanes.J Ethnopharmacol. 2017 May 5;203:110-119. doi: 10.1016/j.jep.2017.03.051. Epub 2017 Mar 28. J Ethnopharmacol. 2017. PMID: 28363522
Cited by
-
β-arrestin 2 is associated with multidrug resistance in breast cancer cells through regulating MDR1 gene expression.Int J Clin Exp Pathol. 2015 Feb 1;8(2):1354-63. eCollection 2015. Int J Clin Exp Pathol. 2015. PMID: 25973019 Free PMC article.
-
A New Strategy for Glioblastoma Treatment: In Vitro and In Vivo Preclinical Characterization of Si306, a Pyrazolo[3,4-d]Pyrimidine Dual Src/P-Glycoprotein Inhibitor.Cancers (Basel). 2019 Jun 19;11(6):848. doi: 10.3390/cancers11060848. Cancers (Basel). 2019. PMID: 31248184 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous